Tetraenone A: A New Β-Ionone Derivative From Tetraena :@0.104762:0.111208:0.813899:0.111208:0.813899:0.083261:0.104762:0.083261:0.016427:0.012680:0.009510:0.012680:0.014279:0.012680:0.015878:0.014279:0.015878:0.012680:0.005555:0.020619:0.009510:0.005569:0.019048:0.007140:0.020619:0.012680:0.020619:0.007140:0.019048:0.009510:0.011109:0.014279:0.015878:0.014279:0.015878:0.012680:0.007140:0.020619:0.012680:0.012680:0.007939:0.014279:0.014279:0.009510:0.007939:0.014279:0.012680:0.007140:0.017449:0.012152:0.014279:0.023789:0.006625:0.016424:0.012680:0.009510:0.012680:0.014279:0.012680:0.015878:0.014279:0.007140
Aegyptia  :@0.104762:0.137337:0.228504:0.137337:0.228504:0.109391:0.104762:0.109391:0.020619:0.012680:0.014279:0.014279:0.015878:0.009510:0.007939:0.014279:0.007140:0.007140
Metabolites. 2023; 13(12): 1202.:@0.342903:0.161953:0.657111:0.161953:0.657111:0.139687:0.342903:0.139687:0.020908:0.010442:0.006538:0.011759:0.011759:0.011759:0.006538:0.006538:0.006538:0.010442:0.009149:0.005880:0.005880:0.011759:0.011759:0.011759:0.011759:0.007832:0.005880:0.011759:0.011759:0.007832:0.011759:0.011759:0.007832:0.007832:0.005880:0.011759:0.011759:0.011759:0.011759:0.005880
------------------------------------------------------------------------------------:@0.171054:0.188078:0.828913:0.188078:0.828913:0.165678:0.171054:0.165678:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832
Ahmed Ashour, Asmaa E. Sherif, Selwan M El-Sayed, Ji-Young Kim, Dae Sik :@0.129221:0.214144:0.876574:0.214144:0.876574:0.192195:0.129221:0.192195:0.015463:0.012889:0.018036:0.010293:0.011591:0.004936:0.015463:0.009018:0.012889:0.011591:0.012889:0.007743:0.005796:0.004936:0.015463:0.009018:0.018036:0.011591:0.011591:0.005796:0.015463:0.005796:0.005796:0.012889:0.012889:0.010293:0.009018:0.006445:0.007720:0.005796:0.005796:0.012889:0.010293:0.006445:0.015463:0.011591:0.012889:0.005796:0.020609:0.005796:0.015463:0.006445:0.007720:0.012889:0.011591:0.010293:0.010293:0.011591:0.005796:0.005796:0.011591:0.006445:0.007720:0.011591:0.011591:0.012889:0.012889:0.011591:0.005796:0.015463:0.006445:0.018036:0.005796:0.005796:0.016738:0.011591:0.010293:0.005796:0.012889:0.006445:0.011591:0.005796
Jang, Abtin Anvari, Abdelbasset A. Farahat, Sabrin R. M. Ibrahim, Gamal A. :@0.130820:0.240272:0.874963:0.240272:0.874963:0.218324:0.130820:0.218324:0.011591:0.011591:0.012889:0.011591:0.005796:0.004933:0.015463:0.011591:0.006445:0.006445:0.012889:0.004933:0.015463:0.012889:0.010293:0.011591:0.009018:0.006445:0.005796:0.004936:0.015463:0.011591:0.011591:0.010293:0.006445:0.011591:0.011591:0.009018:0.009018:0.010293:0.006445:0.004936:0.015463:0.005796:0.005796:0.015463:0.011591:0.009018:0.011591:0.012889:0.011591:0.006445:0.005796:0.005796:0.012889:0.011591:0.011591:0.009018:0.006445:0.012889:0.005796:0.015463:0.005796:0.005796:0.020609:0.005796:0.005796:0.009018:0.011591:0.009018:0.011591:0.012889:0.006445:0.018036:0.005796:0.005796:0.016738:0.011591:0.018036:0.011591:0.006445:0.004936:0.015463:0.005796:0.005796
Mohamed, Bayan E. Ainousah, Raghad F. Aljohani, Razan R. Al-Hejaili, Rahaf :@0.117931:0.266400:0.887885:0.266400:0.887885:0.244452:0.117931:0.244452:0.020609:0.011591:0.012889:0.011591:0.018036:0.010293:0.011591:0.005796:0.005796:0.015463:0.011591:0.010293:0.011591:0.012889:0.005796:0.015463:0.005796:0.004936:0.015463:0.006445:0.012889:0.011591:0.012889:0.009018:0.011591:0.012889:0.005796:0.005796:0.015463:0.011591:0.011591:0.012889:0.011591:0.011591:0.005796:0.012472:0.005796:0.004936:0.015463:0.006445:0.006445:0.011591:0.012889:0.011591:0.012889:0.006445:0.005796:0.005796:0.015463:0.011591:0.009018:0.011591:0.012889:0.005796:0.015463:0.005796:0.004936:0.015463:0.006445:0.007720:0.018036:0.010293:0.006445:0.011591:0.006445:0.006445:0.006445:0.005796:0.005796:0.015463:0.011591:0.012889:0.011591:0.007720:0.005796
H. Khoja, Ahmed H. E. Hassan, Ahmed A. Zaki:@0.272002:0.292529:0.728014:0.292529:0.728014:0.270580:0.272002:0.270580:0.018036:0.005796:0.005796:0.015463:0.012889:0.011591:0.006445:0.011591:0.005796:0.004936:0.015463:0.012889:0.018036:0.010293:0.011591:0.005796:0.018036:0.005796:0.005796:0.015463:0.005796:0.005796:0.018036:0.011591:0.009018:0.009018:0.011591:0.012889:0.005796:0.004933:0.015463:0.012889:0.018036:0.010293:0.011591:0.004933:0.015463:0.005796:0.005796:0.014165:0.011591:0.011591:0.006445
Faculty of Pharmacy Newsletter:@0.147970:0.965677:0.401979:0.965677:0.401979:0.947594:0.147970:0.947594:0.011291:0.009239:0.008205:0.010274:0.005137:0.006153:0.009239:0.004620:0.009239:0.006153:0.004620:0.011291:0.010274:0.009239:0.008205:0.015393:0.009239:0.008205:0.009239:0.004620:0.013342:0.008205:0.013342:0.007188:0.005137:0.008205:0.006153:0.006153:0.008205:0.008205
Reference::@0.104524:0.686031:0.210310:0.686031:0.210310:0.663765:0.104524:0.663765:0.015687:0.010442:0.007832:0.010442:0.009149:0.010442:0.013076:0.010442:0.010442:0.007832
https://doi.org/10.3390/metabo13121202:@0.104524:0.705560:0.379541:0.705560:0.379541:0.689561:0.104524:0.689561:0.008399:0.004670:0.004670:0.008399:0.006535:0.004670:0.004670:0.004670:0.008399:0.008399:0.004670:0.004200:0.008399:0.005277:0.008399:0.004670:0.008399:0.008399:0.004200:0.008399:0.008399:0.008399:0.008399:0.004670:0.013070:0.007459:0.004670:0.007459:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399
Abstract:@0.104762:0.328980:0.213026:0.328980:0.213026:0.301034:0.104762:0.301034:0.020905:0.016164:0.011395:0.009795:0.012965:0.014565:0.012965:0.009510
In this study, the chemical investigation of  Tetraena aegyptia (Zygophyllaceae) led to the :@0.104762:0.350571:0.900442:0.350571:0.900442:0.331372:0.104762:0.331372:0.006914:0.010281:0.009938:0.005806:0.010281:0.005806:0.008043:0.009938:0.008043:0.005806:0.010281:0.010281:0.008973:0.005241:0.009938:0.005806:0.010281:0.009152:0.009938:0.009152:0.010281:0.009152:0.015885:0.005806:0.009152:0.009152:0.005806:0.009938:0.005806:0.010281:0.010281:0.009152:0.008043:0.005806:0.005806:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.009938:0.010281:0.006914:0.005040:0.004532:0.011107:0.009152:0.005806:0.006914:0.009152:0.009152:0.010281:0.009152:0.009938:0.009152:0.009152:0.010281:0.010281:0.010281:0.005806:0.005806:0.009152:0.009938:0.006914:0.012519:0.010281:0.010281:0.010281:0.010281:0.010281:0.010281:0.005806:0.005806:0.009152:0.009152:0.009152:0.009152:0.009152:0.006914:0.009938:0.005806:0.009152:0.010281:0.009938:0.005806:0.010281:0.009938:0.005806:0.010281:0.008948:0.005040
identification of a new megastigmene derivative, tetraenone A ((2S, 5R, 6R, 7E)-2-hydroxy-:@0.104762:0.367676:0.895379:0.367676:0.895379:0.348476:0.104762:0.348476:0.005806:0.010281:0.009152:0.010281:0.005806:0.005806:0.006914:0.005806:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.007842:0.010281:0.006914:0.007842:0.009152:0.007842:0.010281:0.009152:0.014756:0.007842:0.015885:0.009152:0.010281:0.009152:0.008043:0.005806:0.005806:0.010281:0.015885:0.009152:0.010281:0.009152:0.007842:0.010281:0.009152:0.006914:0.005806:0.010281:0.009152:0.005806:0.005806:0.010281:0.009152:0.005241:0.007842:0.005806:0.009152:0.005806:0.006914:0.009152:0.009152:0.010281:0.010281:0.010281:0.009152:0.006725:0.013647:0.007842:0.006914:0.006914:0.010281:0.011410:0.005241:0.007842:0.010281:0.013647:0.005241:0.007842:0.010281:0.013647:0.005241:0.007842:0.010281:0.012519:0.006914:0.006914:0.010281:0.006914:0.010281:0.010281:0.010281:0.006914:0.010281:0.010281:0.010281:0.006713
5,6-dihydro-β-ionone)  (1),  along  with  (3S,  5R,  6S,  7E)-3-hydroxy-5,6-epoxy-5,6-dihydro-β-:@0.104762:0.384780:0.895266:0.384780:0.895266:0.365580:0.104762:0.365580:0.010281:0.005241:0.010281:0.006914:0.010281:0.005806:0.010281:0.010281:0.010281:0.006914:0.010281:0.006914:0.010462:0.006914:0.005806:0.010281:0.010281:0.010281:0.010281:0.009152:0.006914:0.005040:0.004167:0.006914:0.010281:0.006914:0.005241:0.005040:0.004167:0.009152:0.005806:0.010281:0.010281:0.010281:0.005040:0.004167:0.014756:0.005806:0.005806:0.010281:0.005040:0.004167:0.006914:0.010281:0.011410:0.005241:0.005040:0.004169:0.010281:0.013647:0.005241:0.005040:0.004167:0.010281:0.011410:0.005241:0.005040:0.004167:0.010281:0.012519:0.006914:0.006914:0.010281:0.006914:0.010281:0.010281:0.010281:0.006914:0.010281:0.010281:0.010281:0.006914:0.010281:0.005241:0.010281:0.006914:0.009152:0.010281:0.010281:0.010281:0.010281:0.006914:0.010281:0.005241:0.010281:0.006914:0.010281:0.005806:0.010281:0.010281:0.010281:0.006914:0.010281:0.006914:0.010462:0.006713
ionone-  (2),  3,4-dihydroxy-cinnamyl  alcohol-4-glucoside  (3),  3β,19α-dihydroxy-ursan-28-oic :@0.104762:0.401884:0.900340:0.401884:0.900340:0.382685:0.104762:0.382685:0.005806:0.010281:0.010281:0.010281:0.010281:0.009152:0.006914:0.005040:0.003762:0.006914:0.010281:0.006914:0.005241:0.005040:0.003760:0.010281:0.005241:0.010281:0.006914:0.010281:0.005806:0.010281:0.010281:0.010281:0.006914:0.010281:0.010281:0.010281:0.006914:0.009152:0.005806:0.010281:0.010281:0.009152:0.015885:0.010281:0.005806:0.005040:0.003760:0.009152:0.005806:0.009152:0.010281:0.010281:0.010281:0.005806:0.006914:0.010281:0.006914:0.010281:0.005806:0.010281:0.009152:0.010281:0.008043:0.005806:0.010281:0.009152:0.005040:0.003762:0.006914:0.010281:0.006914:0.005241:0.005040:0.003762:0.010281:0.010462:0.005241:0.010281:0.010281:0.010765:0.006914:0.010281:0.005806:0.010281:0.010281:0.010281:0.006914:0.010281:0.010281:0.010281:0.006914:0.010281:0.006914:0.008043:0.009152:0.010281:0.006914:0.010281:0.010281:0.006914:0.010281:0.005806:0.008948:0.005040
acid (4), quinovic acid (5), p-coumaric acid (6), and ferulic acid (7), for the first time. The :@0.104762:0.418989:0.900267:0.418989:0.900267:0.399789:0.104762:0.399789:0.009152:0.009152:0.005806:0.010281:0.008104:0.006914:0.010281:0.006914:0.005241:0.008104:0.010281:0.010281:0.005806:0.010281:0.010281:0.010281:0.005806:0.009152:0.008104:0.009152:0.009152:0.005806:0.010281:0.008104:0.006914:0.010281:0.006914:0.005241:0.008104:0.010281:0.006914:0.009152:0.010281:0.010281:0.015885:0.009152:0.006914:0.005806:0.009152:0.008104:0.009152:0.009152:0.005806:0.010281:0.008104:0.006914:0.010281:0.006914:0.005241:0.008104:0.009152:0.010281:0.010281:0.008104:0.006914:0.009152:0.006914:0.010281:0.005806:0.005806:0.009152:0.008104:0.009152:0.009152:0.005806:0.010281:0.008104:0.006914:0.010281:0.006914:0.005241:0.008104:0.006914:0.010281:0.006914:0.008104:0.005806:0.010281:0.009152:0.008104:0.006914:0.005806:0.006914:0.008043:0.005806:0.008104:0.005806:0.005806:0.015885:0.009152:0.005241:0.007747:0.012519:0.010281:0.008946:0.005040
chemical structures of 1–7 were confirmed by analysis of their 1D and 2D NMR and HRESIMS :@0.104762:0.436093:0.900348:0.436093:0.900348:0.416894:0.104762:0.416894:0.009152:0.010281:0.009152:0.015885:0.005806:0.009152:0.009152:0.005806:0.005080:0.008043:0.005806:0.006914:0.010281:0.009152:0.005806:0.010281:0.006914:0.009152:0.008043:0.005080:0.010281:0.006914:0.005080:0.010281:0.010281:0.010281:0.005080:0.014756:0.009152:0.006914:0.009152:0.005080:0.009152:0.010281:0.010281:0.006914:0.005806:0.006914:0.015885:0.009152:0.010281:0.005080:0.010281:0.010281:0.005080:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.008043:0.005080:0.010281:0.006914:0.005080:0.005806:0.010281:0.009152:0.005806:0.006914:0.005080:0.010281:0.014756:0.005080:0.009152:0.010281:0.010281:0.005080:0.010281:0.014756:0.005080:0.014756:0.018123:0.013647:0.005080:0.009152:0.010281:0.010281:0.005080:0.014756:0.013647:0.012519:0.011410:0.006914:0.018123:0.011210:0.005040
spectra and by their comparison with the relevant literature. The absolute configurations of 1 :@0.104762:0.453198:0.900386:0.453198:0.900386:0.433998:0.104762:0.433998:0.008043:0.010281:0.009152:0.009152:0.005806:0.006914:0.009152:0.007104:0.009152:0.010281:0.010281:0.007106:0.010281:0.010281:0.007106:0.005806:0.010281:0.009152:0.005806:0.006914:0.007106:0.009152:0.010281:0.015885:0.010281:0.009152:0.006914:0.005806:0.008043:0.010281:0.010281:0.007104:0.014756:0.005806:0.005806:0.010281:0.007104:0.005806:0.010281:0.009152:0.007106:0.006914:0.009152:0.005806:0.009152:0.010281:0.009152:0.010281:0.005806:0.007104:0.005806:0.005806:0.005806:0.009152:0.006914:0.009152:0.005806:0.010281:0.006914:0.009152:0.005241:0.006741:0.012519:0.010281:0.009152:0.007106:0.009152:0.010281:0.008043:0.010281:0.005806:0.010281:0.005806:0.009152:0.007106:0.009152:0.010281:0.010281:0.006914:0.005806:0.010281:0.010281:0.006914:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.007106:0.010281:0.006914:0.007106:0.010079:0.005040
and 2 were assigned based on NOESY interactions and ECD spectra. Conformational analysis :@0.104762:0.470302:0.900370:0.470302:0.900370:0.451102:0.104762:0.451102:0.009152:0.010281:0.010281:0.006410:0.010281:0.006410:0.014756:0.009152:0.006914:0.009152:0.006410:0.009152:0.008043:0.008043:0.005806:0.010281:0.010281:0.009152:0.010281:0.006410:0.010281:0.009152:0.008043:0.009152:0.010281:0.006410:0.010281:0.010281:0.006410:0.014756:0.014756:0.012519:0.011410:0.014010:0.006410:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.006410:0.009152:0.010281:0.010281:0.006410:0.012519:0.013647:0.014756:0.006410:0.008043:0.010281:0.009152:0.009152:0.005806:0.006914:0.009152:0.005241:0.006410:0.013647:0.010281:0.010281:0.006914:0.010281:0.006914:0.015885:0.009152:0.005806:0.005806:0.010281:0.010281:0.009152:0.005806:0.006410:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.007846:0.005040
showed that 1 existed exclusively in one of the two theoretically possible chair conformers with :@0.104762:0.487406:0.900467:0.487406:0.900467:0.468207:0.104762:0.468207:0.008043:0.010281:0.010281:0.014756:0.009152:0.010281:0.005161:0.005806:0.010281:0.009152:0.005806:0.005161:0.010281:0.005161:0.009152:0.010281:0.005806:0.008043:0.005806:0.009152:0.010281:0.005161:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.010281:0.009152:0.005806:0.010281:0.005161:0.005806:0.010281:0.005161:0.010281:0.010281:0.009152:0.005161:0.010281:0.006914:0.005161:0.005806:0.010281:0.009152:0.005161:0.005806:0.014756:0.010281:0.005161:0.005806:0.010281:0.009152:0.010281:0.006914:0.009152:0.005806:0.005806:0.009152:0.009152:0.005806:0.005806:0.010281:0.005161:0.010281:0.010281:0.008043:0.008043:0.005806:0.010281:0.005806:0.009152:0.005161:0.009152:0.010281:0.009152:0.005806:0.006914:0.005161:0.009152:0.010281:0.010281:0.006914:0.010281:0.006914:0.015885:0.009152:0.006914:0.008043:0.005161:0.014756:0.005806:0.005806:0.010079:0.005040
a predominant s-trans configuration for the 3-oxobut-1-en-1-yl group with the ring, while the :@0.104762:0.504511:0.900422:0.504511:0.900422:0.485311:0.104762:0.485311:0.009152:0.007015:0.010281:0.006914:0.009152:0.010281:0.010281:0.015885:0.005806:0.010281:0.009152:0.010281:0.005806:0.007015:0.008043:0.006914:0.005806:0.006914:0.009152:0.010281:0.008043:0.007015:0.009152:0.010281:0.010281:0.006914:0.005806:0.010281:0.010281:0.006914:0.009152:0.005806:0.005806:0.010281:0.010281:0.007015:0.006914:0.010281:0.006914:0.007015:0.005806:0.010281:0.009152:0.007015:0.010281:0.006914:0.010281:0.010281:0.010281:0.010281:0.010281:0.005806:0.006914:0.010281:0.006914:0.009152:0.010281:0.006914:0.010281:0.006914:0.010281:0.005806:0.007015:0.010281:0.006914:0.010281:0.010281:0.010281:0.007015:0.014756:0.005806:0.005806:0.010281:0.007015:0.005806:0.010281:0.009152:0.007015:0.006914:0.005806:0.010281:0.010281:0.005241:0.007015:0.014756:0.010281:0.005806:0.005806:0.009152:0.007015:0.005806:0.010281:0.008946:0.005040
half-chair conformer had a pseudo-axial hydroxy group that was predominant over the other :@0.104762:0.521615:0.900265:0.521615:0.900265:0.502415:0.104762:0.502415:0.010281:0.009152:0.005806:0.006914:0.006914:0.009152:0.010281:0.009152:0.005806:0.006914:0.007680:0.009152:0.010281:0.010281:0.006914:0.010281:0.006914:0.015885:0.009152:0.006914:0.007680:0.010281:0.009152:0.010281:0.007680:0.009152:0.007680:0.010281:0.008043:0.009152:0.010281:0.010281:0.010281:0.006914:0.009152:0.010281:0.005806:0.009152:0.005806:0.007680:0.010281:0.010281:0.010281:0.006914:0.010281:0.010281:0.010281:0.007680:0.010281:0.006914:0.010281:0.010281:0.010281:0.007680:0.005806:0.010281:0.009152:0.005806:0.007680:0.014756:0.009152:0.008043:0.007680:0.010281:0.006914:0.009152:0.010281:0.010281:0.015885:0.005806:0.010281:0.009152:0.010281:0.005806:0.007680:0.010281:0.010281:0.009152:0.006914:0.007680:0.005806:0.010281:0.009152:0.007680:0.010281:0.005806:0.010281:0.009152:0.006713:0.005040
half-chair conformation. Boat conformations were not among the most stable conformations, :@0.104762:0.538719:0.900447:0.538719:0.900447:0.519520:0.104762:0.519520:0.010281:0.009152:0.005806:0.006914:0.006914:0.009152:0.010281:0.009152:0.005806:0.006914:0.007620:0.009152:0.010281:0.010281:0.006914:0.010281:0.006914:0.015885:0.009152:0.005806:0.005806:0.010281:0.010281:0.005241:0.007620:0.013647:0.010281:0.009152:0.005806:0.007620:0.009152:0.010281:0.010281:0.006914:0.010281:0.006914:0.015885:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.007620:0.014756:0.009152:0.006914:0.009152:0.007620:0.010281:0.010281:0.005806:0.007620:0.009152:0.015885:0.010281:0.010281:0.010281:0.007620:0.005806:0.010281:0.009152:0.007620:0.015885:0.010281:0.008043:0.005806:0.007620:0.008043:0.005806:0.009152:0.010281:0.005806:0.009152:0.007620:0.009152:0.010281:0.010281:0.006914:0.010281:0.006914:0.015885:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.005040:0.005040
and the s-trans isomerism was in favor of s-cis configuration. In silico investigation revealed :@0.104762:0.555824:0.900265:0.555824:0.900265:0.536624:0.104762:0.536624:0.009152:0.010281:0.010281:0.007136:0.005806:0.010281:0.009152:0.007136:0.008043:0.006914:0.005806:0.006914:0.009152:0.010281:0.008043:0.007136:0.005806:0.008043:0.010281:0.015885:0.009152:0.006914:0.005806:0.008043:0.015885:0.007136:0.014756:0.009152:0.008043:0.007136:0.005806:0.010281:0.007136:0.006914:0.009152:0.010281:0.010281:0.006914:0.007136:0.010281:0.006914:0.007136:0.008043:0.006914:0.009152:0.005806:0.008043:0.007136:0.009152:0.010281:0.010281:0.006914:0.005806:0.010281:0.010281:0.006914:0.009152:0.005806:0.005806:0.010281:0.010281:0.005241:0.007136:0.006914:0.010281:0.007136:0.008043:0.005806:0.005806:0.005806:0.009152:0.010281:0.007136:0.005806:0.010281:0.010281:0.009152:0.008043:0.005806:0.005806:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.007136:0.006914:0.009152:0.010281:0.009152:0.009152:0.005806:0.009152:0.010079:0.005040
that 1 and 2 had more favorable binding interactions with Mpro rather than with TMPRSS2. :@0.104762:0.572928:0.900449:0.572928:0.900449:0.553729:0.104762:0.553729:0.005806:0.010281:0.009152:0.005806:0.007418:0.010281:0.007418:0.009152:0.010281:0.010281:0.007418:0.010281:0.007418:0.010281:0.009152:0.010281:0.007418:0.015885:0.010281:0.006914:0.009152:0.007418:0.006914:0.009152:0.010281:0.010281:0.006914:0.009152:0.010281:0.005806:0.009152:0.007408:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.007418:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.007418:0.014756:0.005806:0.005806:0.010281:0.007418:0.018123:0.010281:0.006914:0.010281:0.007418:0.006914:0.009152:0.005806:0.010281:0.009152:0.006914:0.007418:0.005806:0.010281:0.009152:0.010281:0.007418:0.014756:0.005806:0.005806:0.010281:0.007047:0.012519:0.018123:0.011410:0.013647:0.011410:0.011410:0.010281:0.005040:0.005040
Accordingly, molecular dynamic simulations were performed on the complexes of compounds :@0.104762:0.590033:0.900432:0.590033:0.900432:0.570833:0.104762:0.570833:0.014756:0.009152:0.009152:0.010281:0.006914:0.010281:0.005806:0.010281:0.010281:0.005806:0.008973:0.005241:0.006390:0.015885:0.010281:0.005806:0.009152:0.009152:0.010281:0.005806:0.009152:0.006914:0.006390:0.010281:0.010281:0.010281:0.009152:0.015885:0.005806:0.009152:0.006390:0.008043:0.005806:0.015885:0.010281:0.005806:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.006390:0.014756:0.009152:0.006914:0.009152:0.006390:0.010281:0.009152:0.006914:0.006914:0.010281:0.006914:0.015885:0.009152:0.010281:0.006390:0.010281:0.010281:0.006390:0.005806:0.010281:0.009152:0.006390:0.009152:0.010281:0.015885:0.010281:0.005806:0.009152:0.010281:0.009152:0.008043:0.006390:0.010281:0.006914:0.006390:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.007846:0.005040
1 and 2 with Mpro to explore the stability of their interaction with the target protein structure. :@0.104762:0.607137:0.900424:0.607137:0.900424:0.587937:0.104762:0.587937:0.010281:0.006249:0.009152:0.010281:0.010281:0.006249:0.010281:0.006249:0.014756:0.005806:0.005806:0.010281:0.006249:0.018123:0.010281:0.006914:0.010281:0.006249:0.005806:0.010281:0.006249:0.009152:0.010281:0.010281:0.005806:0.010281:0.006914:0.009152:0.006249:0.005806:0.010281:0.009152:0.006249:0.008043:0.005806:0.009152:0.010281:0.005806:0.005806:0.005806:0.005806:0.010281:0.006249:0.010281:0.006914:0.006249:0.005806:0.010281:0.009152:0.005806:0.006914:0.006249:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.006249:0.014756:0.005806:0.005806:0.010281:0.006249:0.005806:0.010281:0.009152:0.006249:0.005806:0.009152:0.006550:0.010281:0.009152:0.005806:0.006249:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.006249:0.008043:0.005806:0.006914:0.010281:0.009152:0.005806:0.010281:0.006914:0.009152:0.005040:0.005040
Compounds 1 and 2 might offer a possible starting point for developing covalent inhibitors of :@0.104762:0.624241:0.900263:0.624241:0.900263:0.605042:0.104762:0.605042:0.013647:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.008043:0.006410:0.010281:0.006410:0.009152:0.010281:0.010281:0.006410:0.010281:0.006410:0.015885:0.005806:0.010281:0.010281:0.005806:0.006410:0.010281:0.006550:0.006914:0.009152:0.006914:0.006410:0.009152:0.006410:0.010281:0.010281:0.008043:0.008043:0.005806:0.010281:0.005806:0.009152:0.006410:0.008043:0.005806:0.009152:0.006914:0.005806:0.005806:0.010281:0.010281:0.006410:0.010281:0.010281:0.005806:0.010281:0.005806:0.006410:0.006914:0.010281:0.006914:0.006410:0.010281:0.009152:0.010281:0.009152:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.006410:0.009152:0.010281:0.010281:0.009152:0.005806:0.009152:0.010281:0.005806:0.006410:0.005806:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.010281:0.006914:0.008043:0.006410:0.010281:0.006713:0.005040
Mpro of SARS-CoV-2:@0.104762:0.641346:0.295530:0.641346:0.295530:0.622146:0.104762:0.622146:0.018123:0.010281:0.006914:0.010281:0.008003:0.010281:0.006914:0.008003:0.011410:0.014756:0.013647:0.011410:0.006914:0.013647:0.010281:0.012908:0.006914:0.010079
108:@0.085714:0.970956:0.135335:0.970956:0.135335:0.940018:0.085714:0.940018:0.016540:0.016540:0.016540
Chapter V:@0.103809:0.063855:0.209433:0.063855:0.209433:0.040840:0.103809:0.040840:0.016980:0.013076:0.011759:0.013076:0.007832:0.010442:0.010021:0.005456:0.016980